Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Clinical research

Immune checkpoint inhibitor shows activity against bladder cancer

Immune checkpoint inhibitor shows positive results in bladder cancer (pictured, light micrograph)

Source: Steve Gschmeissner / Science Photo Library

Patients with bladder cancer were treated with a new immune checkpoint inhibitor, MPDL3280A

Chemotherapy is the standard of care for metastatic bladder cancer (MBC). A new therapy is now on the horizon involving an immune checkpoint inhibitor, MPDL3280A, which has shown “striking preliminary efficacy and safety results” and has been granted breakthrough status by the US Food and Drug Administration.

MPDL3280A is an antibody against programmed death-ligand 1 (PD-L1), a protein expressed by activated T-cells. In a Phase I study involving 68 patients with MBC, published in Nature (online, 26 November 2014)[1], 27% were found to have PD-L1-positive tumours. After six weeks of treatment, 43% of patients with PD-L1-positive tumours had an objective response, rising to 52% after 12 weeks. Two patients (7%) had a complete response.

MPDL3280A was well tolerated, with adverse event rates similar or lower than those seen with standard chemotherapy.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067327

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.